1Langer O, Conway DL, Berkus MD, et al. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med, 2000, 343: 1134-1138.
2Jacobson GF, Ramos GA, Ching JY, et al. Comparison of glyburide and insulin for the management of gestational diabetes in a large managed care organization. Am J Obstet Gynecol, 2005, 193: 118-124.
3Bertini AM, Silva JC, Taborda W, et al. Perinatal outcomes and the useof oral hypoglycemic agents. J Perinat Med, 2005, 33: 519-523.
4Silva JC, Bertini AM, Taborda W, et al. Glibenclamide in the treatment for gestational diabetes mellitus in a compared study to insulin. Arq Bras Endocrinol Metab, 2007, 51: 541-546.
6Shepard TH. Catalog of teratogenie agents. Johns Hopkins University Press, 1995:202.
7Piacquadio K, Hollingsworth DR, Murphy H. Effects of in-utero exposure to oral hypoglycaemic drugs. Lancet, 1991, 338: 866.
8Botta RM. Congenital malformations in infants of 517 pregestational diabetic mothers. Ann Ist Super Sanita, 1997, 33: 307-311.
9Gutzin SJ, Kozer E, Magee LA, et al. The safety of oral hypoglycemic agents in the first trimester of pregnancy: a meta-analysis. Can J Clin Pharmacol, 2003, 10: 179-183.
10Elliot B, Langer O, Schussling F. A model of human placental drug transfer. Am J Obstet Gynecol, 1997, 176: 527-530.
9Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report ot the Experl Committee on the Diagnosis and Classification of Diabetes Mellitus[J]. Diabetes Care,2000,23 (Suppl 1):S4- 19.
10Wolf M, Sauk J, Shah A, et al. Inflammation and glucose intolerancc:a prospective study of gestational diabetes mellitus[J].Diabetes Care,2001,27(1) :21-27.
